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Abstract. 
 
Differentiation of skeletal muscle myoblasts 
follows an ordered sequence of events: commitment, 
cell cycle withdrawal, phenotypic differentiation, and ﬁ-
nally cell fusion to form multinucleated myotubes. The 
molecular signaling pathways that regulate the progres-
sion are not well understood. Here we investigate the 
potential role of calcium and the calcium-dependent 
phosphatase calcineurin in myogenesis. Commitment, 
phenotypic differentiation, and cell fusion are identiﬁed 
as distinct calcium-regulated steps, based on the extra-
cellular calcium concentration required for the expres-
sion of morphological and biochemical markers speciﬁc 
to each of these stages. Furthermore, differentiation is 
inhibited at the commitment stage by either treatment 
with the calcineurin inhibitor cyclosporine A (CSA) or 
expression of CAIN, a physiological inhibitor of cal-
cineurin. Retroviral-mediated gene transfer of a consti-
tutively active form of calcineurin is able to induce 
myogenesis only in the presence of extracellular cal-
cium, suggesting that multiple calcium-dependent path-
ways are required for differentiation. The mechanism 
by which calcineurin initiates differentiation includes 
transcriptional activation of myogenin, but does not
require the participation of NFAT. We conclude that 
commitment of skeletal muscle cells to differentiation 
is calcium and calcineurin-dependent, but NFAT-inde-
pendent.
Key words: calcium • myogenesis • signal transduc-
tion • calcineurin • myogenin
 
Introduction
 
Development of skeletal muscle consists of a highly regu-
lated, temporally distinct sequence of events. A model for
myogenesis has been proposed by Andres et al. (1996)
based on immunofluorescence studies of single cells. In
this model, myoblasts first commit to the differentiation
pathway, a step marked by the expression of the bHLH
transcription factor myogenin, followed by terminal cell
cycle withdrawal and the induction of the cell cycle inhibi-
tor p21. In later stages of myogenesis, the cells phenotypi-
cally differentiate, marked by contractile gene expression,
and then fuse into multinucleated myotubes. That commit-
ment and cell cycle withdrawal is required before pheno-
typic differentiation and cell fusion is supported by both in
vivo
 
 
 
and in vitro studies. Mice lacking myogenin have a se-
vere reduction in the appearance of muscle-specific pro-
teins and myotubes (Hasty et al., 1993). Inactivation of
two apparently redundant cell cycle inhibitors, p21 and
p57, results in a phenotype nearly identical to the inactiva-
tion of myogenin (Zhang et al., 1999). Treatment of
BC3H-1 cells with a myogenin antisense oligomer blocks
myoblast fusion and results in nearly complete inhibition
of acetylcholine receptor protein expression (Brunetti and
Goldfine, 1990). That phenotypic differentiation precedes
cell fusion is supported by numerous studies showing ex-
pression of differentiation specific proteins such as acetyl-
choline receptors (Merlie and Gros, 1976; Bar-Sagi and
Prives, 1983), creatine kinase (Merlie and Gros, 1976;
Morris and Cole, 1979), myosin heavy chain (Merlie and
Gros, 1976; Andres and Walsh, 1996), p21, and myogenin
(Andres and Walsh, 1996) in mononucleated cells. In addi-
tion, fusion-arrested myoblasts have excitation and con-
traction properties characteristic of myotubes (Constantin
et al., 1995).
Calcium regulates several of the later steps required for
muscle development. Phenotypic differentiation can be in-
hibited by lowering extracellular calcium concentration
(Shainberg et al., 1969; Morris and Cole, 1979), the addi-
tion of EGTA (Morris and Cole, 1979; Salzberg et al.,
1995), and the addition of L-type calcium channel inhibi-
tors or the depletion of intracellular calcium stores (Seig-
neurin-Venin et al., 1996). The molecular mechanisms by
which calcium regulates phenotypic differentiation are un-
known. Myoblast fusion also demonstrates a requirement
 
Address correspondence to Dr. Grace K. Pavlath, Emory University
School of Medicine, Dept. of Pharmacology, Room 5027, O.W. Rollins
Research Bldg., Atlanta, GA 30322. Tel.: (404) 727-3353. Fax: (404) 727-
0365. E-mail: gpavlat@emory.edu 
The Journal of Cell Biology, Volume 149, 2000 658
 
for calcium (Shainberg et al., 1969; Knudsen and Horwitz,
1977), and several molecular targets for calcium have been
identified. Calcium is required for glycoprotein interac-
tions at the cell surface (Knudsen, 1985; Knudsen et al.,
1990), regulation of cell surface protein phosphorylation
(Lognonne and Wahrmann, 1986), and regulation of cal-
pain-induced proteolysis of proteins involved in mem-
brane-cytoskeleton stability (Barnoy et al., 1997, 1998;
Temm-Grove et al., 1999).
We propose that calcineurin, a calcium-calmodulin–reg-
ulated serine/threonine protein phosphatase, is a molecu-
lar target of calcium in the regulation of skeletal muscle
differentiation at a step before phenotypic differentiation.
In previous work, we demonstrated that the calcineurin in-
hibitor, CSA, blocks differentiation based on the dose-
dependent inhibition of creatine kinase and embryonic
myosin heavy chain (EMyHC)
 
1
 
 expression and the forma-
tion of multinucleated myotubes (Abbott et al., 1998), sug-
gesting a role for calcineurin in the early stages of myogen-
esis. However, other cellular targets besides calcineurin may
exist for CSA in muscle cells (Lo Russo et al., 1996, 1997).
Calcineurin-dependent pathways involving fiber type de-
termination and hypertrophy have been previously de-
scribed in skeletal muscle. Enhancer elements responding
to the calcineurin-regulated transcription factor nuclear
factor of activated T cells (NFAT) have been identified in
the promoters of slow fiber-specific genes (Chin et al.,
1998) and transgenic mice expressing an activated form of
calcineurin display an increase in the number of slow fi-
bers (Naya et al., 2000). Hypertrophy of skeletal muscle in
response to IGF-1 (Musaro et al., 1999; Semsarian et al.,
1999) and to functional overload (Dunn et al., 1999) re-
quires calcineurin activity.
In this study, we test the hypothesis that calcineurin is a
key mediator of calcium signals early in the myogenic pro-
gram using biochemical and genetic modulators of cal-
cineurin activity. We show that in addition to phenotypic
differentiation and cell fusion, calcium is required for the
commitment to the differentiation pathway. Calcineurin is
a necessary molecular target of calcium at the commit-
ment stage and is sufficient, in the presence of adequate
calcium, to induce skeletal muscle cells to initiate differen-
tiation. We find that transcriptional activation of myoge-
nin is a component of calcineurin signaling during differ-
entiation, but that NFAT is not a required element of
the signaling pathway. We conclude that myogenesis is
initiated by a calcineurin-dependent, NFAT-independent
pathway.
 
Materials and Methods
 
Antisera and Reagents
 
Mouse monoclonal antibodies against 
 
a
 
-sarcomeric actin (s-actin) and
 
a
 
-tubulin were purchased from Sigma-Aldrich as ascites fluid. Mouse
monoclonal antibodies against myogenin (Wright et al., 1991) and EMyHC
(Webster et al., 1988) were obtained from the Developmental Studies Hy-
bridoma Bank at the University of Iowa (Iowa City, IA) and used as hy-
bridoma supernatants. Secondary antibodies were purchased from The
Jackson Laboratory. CSA was a gift of Sandoz (Basil, Switzerland). Iono-
mycin and PMA were purchased from Sigma-Aldrich. Amphotropic ret-
roviral producer cells (SD-3443) were obtained from the American Type
Culture Collection. All cell culture reagents were purchased from Life
Technologies, except where noted. Fetal bovine serum (FBS) was pur-
chased from Atlanta Biologicals. Basic fibroblast growth factor (bFGF)
was purchased from Promega. A plasmid containing an activated form of
calcineurin (pCI-neo-CnA*) was a gift of Dr. Rhonda Bassel-Duby (Chin
et al., 1998). A plasmid containing a dominant-negative inhibitor of
NFAT (pGFP-VIVIT) was a gift of Dr. Anjana Rao (Aramburu et al.,
1999). Plasmids containing portions of the myogenin promoter were ob-
tained from Drs. Helen Blau, Nadia Rosenthal, and Rhonda Bassel-
Duby.
 
Cell Culture
 
Primary myoblast cultures were prepared from SJL mice and purified to
 
.
 
99% as previously described (Abbott et al., 1998; Rando and Blau,
1994). Growth media (GM) consisted of Ham’s F10, 20% FBS, 5 ng/ml
bFGF, 200 U/ml penicillin G, and 200 
 
m
 
g/ml streptomycin. The myoblast
cell line L6 was grown in L6 Growth Media (LGM) consisting of DMEM,
10% FBS, 200 U/ml penicillin G, and 200 
 
m
 
g/ml streptomycin. Differentia-
tion was induced by changing primary cells grown on E-C-L (Upstate Bio-
technology)–coated dishes or L6 cells on uncoated dishes to a low serum,
low mitogen differentiation media (DM: DME (1.4 mM Ca
 
2
 
1
 
), 2% horse
serum (HS), 200 U/ml penicillin G, 200 
 
m
 
g/ml streptomycin) for 24–48 h.
Calcium-free differentiation media (DM-CF) was prepared using CaCl
 
2
 
-
free DME and HS that had been dialyzed twice against PBS using a mem-
brane with a 3,500-kD molecular mass cutoff. DM-CF has a residual cal-
cium concentration of at least 8 
 
m
 
M due to calcium pantothenate in the
DME and calcium remaining in dialyzed HS. When necessary, CaCl
 
2
 
 was
added to DM-CF to the desired calcium concentration. Cells were photo-
graphed on a Nikon TMS inverted microscope with a Polaroid MicroCam.
 
Retroviral Plasmids, Production and Infection, and 
FACS
 
®
 
 Sorting
 
The retroviral NFAT-responsive plasmid (pKA7) contains a luciferase
coding sequence under the control of a minimal IL-2 promoter with an up-
stream triplex of the distal IL-2 gene NFAT response element (Abbott et
al., 1998; Boss et al., 1998). The activated calcineurin A (aCnA) expres-
sion plasmid was constructed in the retroviral plasmid pTJ66 in which ex-
pression of the cDNA insert is driven by the viral 5
 
9
 
-LTR promoter (Mur-
phy et al., 2000). pTJ66 contains a chimeric GFP-zeocin selectable marker
driven by IRES-dependent translation that allows the efficiency of retrovi-
ral mediated gene delivery to be assessed by fluorescence microscopy. An
aCnA cDNA was obtained by EcoRI digestion of the plasmid pCI-neo-
CnA* (Chin et al., 1998). The insert was subcloned into SfiI sites in pTJ66
after blunt-end ligation of SfiI adapters to the insert. The CAIN retroviral
expression plasmid was made by using RT-PCR of mouse skeletal muscle
RNA to generate a cDNA corresponding to amino acids 1,989–2,182 of
the rat CAIN sequence, a portion adequate to inhibit calcineurin activity
(Taigen et al., 2000). RT-PCR primers were made corresponding to amino
acids 1,989–1,994 for the forward primer and 2,182–2,178 for the reverse
primer of the rat sequence. The cDNA was subcloned into the retroviral
vector pCL1 (Murphy et al., 2000) in which expression of CAIN is driven
by the 5
 
9
 
 LTR. The GFP-VIVIT retroviral expression plasmid was made
by restriction digest of the vector pGFP-VIVIT (Aramburu et al., 1999) to
generate a cDNA that was subcloned into pCL1. A retroviral reporter
plasmid was created using a portion of the myogenin promoter containing
1,565-bp of upstream promoter sequence (pMyogLuc). A promoter frag-
ment was generated by restriction digest of the plasmid pMyo1565lacZ
and was subcloned into the vector pCatCul (Murphy et al., 2000). The
myogenin promoter drives the transcription of a luciferase gene.
Production of infectious retrovirus and infection of primary myoblasts
were performed as previously described (Abbott et al., 1998). The effi-
ciency of one round of retroviral infection was estimated at 
 
.
 
60% and
 
.
 
90% after two rounds, based on visualization of GFP-positive cells. In
some experiments, GFP-positive cells were further purified by flow cy-
tometry. After infection, cells were grown for 2–3 passages, and the top
50% of GFP expressing cells were sorted and used for further experi-
ments.
 
1
 
Abbreviations used in this paper: 
 
aCnA, activated form of calcineurin A;
CSA, cyclosporine A; DM, differentiation medium; DM-CF, calcium-free
differentiation medium; EMyHC, embryonic myosin heavy chain; GM,
growth medium; HS, horse serum; MEF, myocyte enhancer factor; NFAT,
nuclear factor of activated T cells; s-actin, 
 
a
 
-sarcomeric actin; TBS-T, TBS
containing Tween 20. 
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Reporter Assays
 
NFAT Reporter Assays. 
 
Primary or L6 myoblasts were plated at 4 
 
3
 
 10
 
4
 
cells per well of 24-well dishes. Cells were infected by two rounds of infec-
tion with retroviruses appropriate to each experiment. After 24 h, the me-
dium was replaced with DM and the cells were allowed to differentiate for
48 h. The medium was replaced with the appropriate drug containing me-
dia and incubated for 5–6 h at 37
 
8
 
C. Cells were washed twice with PBS
and 75 
 
m
 
l of Luciferase Cell Culture Lysis Reagent (Promega) was added
to each well. The cell lysates were collected and spun at 12,000 
 
g
 
 for 30 s.
100 
 
m
 
l of Luciferase Assay Reagent (Promega) was injected into 20 
 
m
 
l of
cell lysate and light output was measured after a 5-s delay over a 10-s win-
dow using a Turner TD-20e luminometer (Turner Designs).
 
Myogenin Promoter Reporter Assays. 
 
Primary myoblasts that had been
previously infected with pMyogLuc retrovirus were plated as above and
infected with two rounds of control or aCnA retroviruses. After 48 h in
GM, the cells were lysed and luciferase levels were determined as above.
 
Immunoblotting
 
Cells were lysed with RIPA-2 (50 mM Tris-HCl, pH 8.0, 150 mM NaCl,
1% NP-40, 0.5% deoxycholic acid, 0.1% SDS) containing protease inhibi-
tors (Mini Complete; Boehringer). Equal amounts of protein (5–10 
 
m
 
g per
lane; Bradford, 1976) were separated by SDS-PAGE and transferred elec-
trophoretically to a PVDF membrane (Immobilon P; Millipore). After
nonspecific binding was blocked in 5% nonfat milk in TBS for 30 min, the
membrane was incubated overnight in 0.5% nonfat milk in TBS contain-
ing primary antibodies. Primary antibody dilutions were as follows: anti-
EMyHC, 1:4; anti–s-actin 1:1,000; anti–
 
a
 
-tubulin, 1:1,000; anti-myogenin,
1:10. Blots were washed extensively in TBS containing 0.1% Tween-20
(TBS-T) and then incubated with a goat anti–mouse HRP-conjugated sec-
ondary antibody (1:10,000) in 0.5% nonfat milk in TBS-T. Blots were
washed in TBS-T and antibody binding was detected using ECL reagents
(Amersham Pharmacia Biotech). To demonstrate relative protein load-
ing, SDS-PAGE gels or membranes were stained with Coomassie blue
(Bio-Rad) or membranes were stained with colloidal gold (Bio-Rad).
 
Northern Blotting
 
RNA was prepared from cells using Trizol Reagent (Life Technologies)
following the manufacturer’s protocol. RNA was separated on 1% aga-
rose-formaldehyde gels and transferred to Nytran SPC membranes
(Schleicher & Schuell). Membranes were probed with random-primed
cDNA (Rediprime II; Amersham Pharmacia Biotech) labeled with 
 
32
 
P in
Rapid-hyb buffer (Amersham Pharmacia Biotech). After high-stringency
washing, membranes were visualized by autoradiography.
 
Results
 
Calcium Is Required for Multiple Phases of Myogenesis
 
To investigate the requirement for calcium at each phase
of myogenesis (commitment, phenotypic differentiation,
and cell fusion), myoblasts were induced to differentiate in
a calcium-free DM containing different concentrations of
exogenously added calcium. As shown in Fig. 1 a, primary
myoblasts show a dose-dependent requirement of calcium
for myoblast alignment and fusion. At 50 
 
m
 
M exogenously
added Ca
 
2
 
1
 
, rounded, mononucleated cells are the pre-
dominant cell type. As the calcium is increased to 300 
 
m
 
M,
the cells are still predominantly mononucleated, but the
cells have elongated and aligned next to each other. Signif-
icant fusion of myoblasts is not seen until 1,500 
 
m
 
M Ca
 
2
 
1
 
.
To determine the requirement for calcium in myogenic
phases that can not be distinguished morphologically, we
performed immunoblot analyses using antibodies against
myogenin, and the sarcomeric proteins EMyHC and actin,
markers of commitment and phenotypic differentiation,
respectively (Fig. 1 b). All of these markers display a dose-
dependent increase in expression in response to increasing
concentrations of extracellular Ca
 
2
 
1
 
. Myogenin shows sig-
nificant expression at 25–50 
 
m
 
M Ca
 
2
 
1
 
, whereas EMyHC
and s-actin are not expressed until 150 
 
m
 
M Ca
 
2
 
1
 
. As
shown in Fig. 1 c, the inhibition of differentiation in cal-
cium-free media is reversible, suggesting that it is not due
to cytotoxicity. After readdition of calcium to the media,
the cells express myogenin and EMyHC. Thus, these data
suggest that at least three distinct steps in myogenesis are
regulated by calcium based on the differing calcium re-
quirements of commitment (25–50 
 
m
 
M), phenotypic dif-
ferentiation (150 
 
m
 
M), and cell fusion (1,500 
 
m
 
M).
 
Calcineurin Activity Is Necessary for
Myogenic Commitment
 
Calcineurin is a potential downstream effector of calcium
during myogenesis. The importance of calcineurin in mus-
Figure 1. Extracellular calcium is required for myoblast fusion
and the expression of markers of myogenic commitment and dif-
ferentiation. Primary myoblasts were induced to differentiate in
DM-CF containing the indicated concentrations of exogenously
added calcium for 24 h. (a) Phase-contrast images of cells grown
in 50, 300, and 1,500 mM added calcium. Mononucleated cells are
seen at both 50 and 300 mM Ca21, but the cells become elongated
and align at 300 mM. At 1,500 mM Ca21, mononucleated cells fuse
into multinucleated myotubes. (b) Immunoblots were performed
using antibodies against markers of distinct myogenic phases. Ex-
tracellular calcium is required for significant expression of all the
markers tested. A portion of a Coomassie-stained gel demon-
strates relative protein loading. These results are representative
of three independent experiments. (c) After 24 h in DM-CF con-
taining no exogenously added calcium, cells were either main-
tained in the same media or changed to DM-CF containing 1,500
mM Ca21 for an additional 24 h. Immunoblots demonstrate that
the cells retain the ability to differentiate after the readdition of
calcium. A portion of a Coomassie-stained gel demonstrates rela-
tive protein loading. Bar, 30 mm. 
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cle differentiation is suggested by our previous studies
demonstrating that CSA blocks phenotypic differentiation
and fusion. CSA could directly inhibit each of these
phases, or CSA could act earlier at the commitment stage.
To determine the phase of myogenesis in which CSA ex-
erts its effect, we induced L6 myoblasts to differentiate
in media containing CSA (Fig. 2). At various times af-
ter changing cells to DM, proteins were collected and
analyzed by immunoblotting using antibodies against
myogenin and EMyHC. Myogenin is expressed in vehi-
cle-treated cells at 24 h after inducing differentiation,
whereas EMyHC is first detected at 48 h. CSA reduces the
level of myogenin expression compared with control cells
to 
 
z
 
11% at 24 h and to 
 
z
 
35% at 48 h. EMyHC expression
is undetectable in CSA-treated cells. Since CSA inhibits
the expression of myogenin, then calcineurin is a likely
component of the signaling pathways that initiate commit-
ment, the first step of myogenesis.
CSA may have effects on skeletal muscle cells distinct
from its actions on calcineurin. To conclusively demon-
strate that calcineurin activity is required for the commit-
ment stage, we tested the effect of a novel protein inhibi-
tor of calcineurin on myogenesis. CAIN is a natural
protein product identified by its ability to bind to cal-
cineurin. It has been shown to inhibit calcineurin activity
using in vitro phosphatase assays (Lai et al., 1998) and by
indirectly inhibiting transcription from a reporter respond-
ing to the calcineurin target NFAT (Taigen et al., 2000).
We first expressed CAIN in the presence of an NFAT re-
porter to test for inhibition of calcineurin activity in skele-
tal muscle cells (Fig. 3 a). This reporter requires the cal-
cineurin-induced nuclear translocation of NFAT and the
induction of AP-1 for transcription of the luciferase
cDNA. Stimulation with ionomycin, to activate calci-
neurin, and PMA, to induce AP-1, in control cells results
in an 
 
z
 
32-fold increase in luciferase levels compared with
vehicle-treated control cells. In cells expressing CAIN,
ionomycin and PMA treatment yields only an approxi-
mately fivefold increase. Thus, CAIN effectively inhibits
calcineurin in skeletal muscle cells. In further experiments,
L6 myoblasts were infected with a CAIN retrovirus and
changed to DM to test whether myogenesis would be in-
hibited (Fig. 3 b). In L6 cells infected with the CAIN retro-
virus, myogenin expression is reduced to 
 
z
 
7% of control
cell levels at 24 h and to 
 
z
 
39% at 48 h. EMyHC was unde-
tectable in CAIN-expressing cells. We obtained similar re-
sults in primary muscle cells (data not shown). As both
CSA and CAIN inhibit myogenin and EMyHC expres-
sion, we conclude that calcineurin is an essential mediator
of the signaling required for myogenesis to occur.
 
Calcineurin Activity Is Sufficient to
Induce Differentiation
 
To determine if calcineurin activity is sufficient to induce
myogenic differentiation, we constructed a retroviral vec-
tor that allows for high efficiency gene transfer of a consti-
tutively active form of calcineurin (aCnA). Originally de-
scribed as a proteolytic fragment of calcineurin, aCnA
retains its catalytic activity and sensitivity to CSA, but
no longer requires calcium for activity (Manalan and Klee,
1983; O’Keefe et al., 1992). An NFAT responsive lu-
ciferase reporter was used to indirectly test the activity of
aCnA in skeletal muscle cells. Cells infected with either
control or aCnA retroviruses were induced to differentiate
and then treated with vehicle or PMA. Some cultures were
pretreated with CSA. As seen in Fig. 4 a, luciferase activ-
ity is increased by only 
 
z
 
1.6-fold in control cells with
PMA treatment. By contrast, luciferase activity is in-
creased in aCnA-infected cells by approximately ninefold.
The response to PMA is blocked by the addition of CSA.
These results confirm the activity of aCnA in skeletal mus-
cle cells.
To examine the effect of aCnA on induction of myo-
genic differentiation, primary myoblasts were infected
Figure 2. CSA inhibits myogenic commitment and differentia-
tion. L6 myoblasts were induced to differentiate in DM contain-
ing either vehicle or 1 mM CSA. Cellular proteins were collected
at various time points and analyzed for expression of myogenic
markers. In control cells, expression of myogenin and EMyHC is
first detected at 24 and 48 h, respectively. In CSA-treated cells,
the expression of myogenin is decreased, and EMyHC is unde-
tectable. A portion of a Coomassie-stained gel demonstrates rel-
ative protein loading.
Figure 3. Inhibition of calcineurin activity by
CAIN inhibits myogenesis in L6 muscle cell cul-
tures. (a) L6 myoblasts were infected with an
NFAT reporter and either control (Ctrl) or
CAIN retroviruses. The cells were induced to dif-
ferentiate in DM for 48 h before drug treatment.
Luciferase assays were performed on vehicle (V),
ionomycin (I, 1 mM) plus PMA- (P, 10 nM), or IP
plus CSA- (C, 1 mM) treated cultures. CAIN in-
hibits calcineurin in skeletal muscle cultures
based on the reduction in luciferase activity in IP-treated cultures. Data are reported as the fold increase over vehicle-treated control
cells. Each bar represents the mean 6 SEM of three independent experiments each performed in triplicate. (b) L6 myoblasts were in-
fected with either control or CAIN expression retroviruses and induced to differentiate in DM. Cellular proteins were collected at vari-
ous time points and analyzed by immunoblotting. CAIN reduces the expression level of both myogenic markers. A portion of a Coo-
massie-stained membrane demonstrates relative loading of proteins. The blot shown is representative of two independent experiments. 
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with either control or aCnA retroviruses and maintained
in GM that contains 300 
 
m
 
M Ca
 
2
 
1
 
 and mitogenic stimuli
from both FBS and exogenously added bFGF. Within 48 h
after infection, aCnA-infected cells undergo morphologi-
cal changes consistent with differentiation, including align-
ment and elongation (Fig. 4 b). The majority of the cells
are mononucleated, but occasional multinucleated cells
are observed. The cells appear similar to myoblasts in-
duced to differentiate in DM-CF containing 300 
 
m
 
M Ca
 
2
 
1
 
(Fig. 1 a). The morphological changes are blocked by the
addition of CSA to the media, indicating that the effect is
specific to the expression of aCnA and not an artifact of
the infection protocol. The biochemical differentiation of
the aCnA-infected cells was assayed by immunoblot anal-
yses using antibodies against markers of myogenic com-
mitment and differentiation (Fig. 4 b). aCnA-infected cells
express myogenin, EMyHC and s-actin. None of these
markers are detected in either control cells or in aCnA-
infected cells in the presence of CSA. Thus, calcineurin ac-
tivity is sufficient to initiate differentiation even in the
presence of mitogenic stimuli.
 
Multiple Calcium-dependent Pathways
Initiate Myogenesis
 
Myogenesis initiated by changing cells from GM to DM
requires extracellular calcium (Fig. 1). If calcineurin was
the only calcium-dependent pathway required for differ-
entiation, aCnA should allow myogenesis to occur in cal-
cium-free DM. To test this hypothesis, primary myoblasts
were infected with either control or aCnA retroviruses
and induced to differentiate in calcium-free DM in the
presence of different concentrations of exogenously added
calcium. Immunoblots were performed using an antibody
against myogenin (Fig. 5). At 0 
 
m
 
M Ca
 
2
 
1
 
, neither control
nor aCnA-infected cells express myogenin. At 50 
 
m
 
M
Ca
 
2
 
1
 
 and 1,500 
 
m
 
M Ca
 
2
 
1
 
, myogenin is expressed at equiva-
lent levels in cells infected with either virus. To confirm
that the absence of myogenin expression at 0 
 
m
 
M Ca
 
2
 
1
 
 was
due to the inability of aCnA to substitute for the calcium
requirement and not due to inefficient infection, some cul-
tures were maintained in GM. aCnA induces the expres-
sion of myogenin in these cells compared with control
cells. Myogenin is detected in control cells maintained in
GM (compare to Fig. 4 c), most likely due to spontaneous
differentiation as a result of cell confluency. Therefore,
aCnA is not able to substitute for the calcium requirement
during commitment to differentiation, indicating that cal-
cium is necessary for multiple downstream molecular tar-
gets. Thus, calcineurin activity is sufficient to induce dif-
ferentiation only in the presence of adequate levels of
calcium.
Figure 4. A constitutively ac-
tive form of calcineurin in-
duces myogenic differentia-
tion in primary myoblasts
under growth promoting con-
ditions. (a) Primary myo-
blasts containing an NFAT
responsive reporter con-
struct were infected with ei-
ther control (Ctrl) or aCnA
retroviruses. After 48 h, the
cells were induced to differ-
entiate by changing to DM
for 24 h. Luciferase assays
were performed on vehicle-
(V) or PMA- (P, 10 nM)
treated cultures. Some cul-
tures were pretreated with 1
mM CSA. aCnA expression
increases luciferase levels
compared with control cells
in PMA-treated cultures.
aCnA is sensitive to inhibi-
tion by CSA. Data are re-
ported as the fold increase
over vehicle-treated control
cells. Each bar represents the
mean 6 SEM of three independent experiments each performed in duplicate. (b and c) Primary myoblasts underwent two rounds of in-
fection with either control (Ctrl) or aCnA retroviruses. CSA (1 mM) was added to some cultures after the second infection. (b) Phase-
contrast images of cells 48 h after infection. aCnA induces morphologic changes indicative of myogenic differentiation, including cell
elongation, cell alignment, and occasional cell fusion. The morphologic changes are blocked by the addition of CSA to the media. (c) 48 h
after infection, proteins were collected and analyzed by immunoblotting for markers of commitment and differentiation. Expression
of aCnA results in induction of multiple myogenic markers, which can be blocked with CSA. The expression of the nonmyogenic
protein a-tubulin demonstrates equivalent loading of proteins. These results are representative of three independent experiments. Bar,
30 mm. 
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Transcriptional Activation of Myogenin Is a Component 
of aCnA-induced Differentiation
 
Expression of myogenin mRNA and protein mark the
transition from a proliferative myoblast to a cell commit-
ted to the differentiation pathway. Expression of aCnA
can induce differentiation and results in an increase in
myogenin protein expression. The increase in the level of
myogenin protein could be accounted for by stabilization
of either the mRNA or the protein, or by an increase in
transcription or translation. To determine the mechanism
for the increase in myogenin protein we performed North-
ern blot analyses on RNA isolated from primary muscle
cells infected with either control or aCnA retroviruses
(Fig. 6 a). Compared with control cells, the levels of myo-
genin mRNA increase in aCnA-infected cells at both 24
and 48 h after infection. Therefore, mRNA stabilization or
transcriptional activation could account for the increase in
myogenin protein levels.
To examine transcriptional activation of the myogenin
promoter by aCnA, we constructed a retroviral reporter
 
plasmid that contains 1,565 bp of upstream promoter se-
quence from the myogenin gene driving luciferase expres-
sion. Primary muscle cells containing pMyogLuc were in-
fected with either control or aCnA retroviruses (Fig. 6 b).
Luciferase assays were performed on cells after 48 h in
GM. Compared with control cells, luciferase levels in-
crease by 
 
z
 
20% in aCnA-infected cells. The increase was
not seen with CSA treatment demonstrating that the in-
crease is specific to the expression of aCnA. We conclude
that transcriptional activation of the myogenin gene repre-
sents a downstream target of calcineurin activity in myo-
genesis.
 
NFAT Is Not a Required Downstream Target of 
Calcineurin during Myogenesis
 
Transcriptional activation is at least one mechanism
whereby calcineurin regulates differentiation. To deter-
mine if the transcription factor NFAT is a required down
stream target of calcineurin during differentiation, we
used a peptide inhibitor of NFAT, GFP-VIVIT (Aram-
buru et al., 1999). We have shown previously that three
NFAT isoforms are expressed in skeletal muscle and are
able to translocate to the nucleus at different stages of
myogenesis (Abbott et al., 1998). To test whether GFP-
VIVIT inhibits NFAT activity in skeletal muscle cells, pri-
mary myoblasts were infected with an NFAT reporter and
either control or GFP-VIVIT retroviruses and sorted for
GFP expression by flow cytometry (Fig. 7 a). Myoblasts
were induced to differentiate in DM for 48 h, followed by
treatment with ionomycin and PMA for 5 h. Some cultures
were also treated with CSA. In control cells, luciferase lev-
els increase 
 
z
 
25-fold, whereas levels in GFP-VIVIT–
infected cells increase only 
 
z
 
1.3-fold demonstrating that
GFP-VIVIT effectively inhibits NFAT activity in skeletal
muscle cells.
To determine if NFAT activity is required during differ-
entiation, L6 muscle cells were infected with either control
or GFP-VIVIT retroviruses and induced to differentiate in
DM. Immunoblot analysis was performed on cellular pro-
teins using antibodies against myogenin and EMyHC (Fig.
7 b). GFP-VIVIT expression does not inhibit the expres-
sion of either myogenin or EMyHC. Paradoxically, we see
a slight increase in expression of both markers after 24 h in
DM. We obtained similar results in primary muscle cells
Figure 5. Multiple calcium-dependent pathways are necessary
for initiating myogenesis. Myoblasts were infected with either
control (Ctrl) or aCnA retroviruses. Cells were maintained in
GM for 6 h and then induced to differentiate in DM-CF contain-
ing different concentrations of exogenously added calcium for
36 h. Some cultures were kept in GM for the entire experiment.
Cellular proteins were analyzed by immunoblotting using an an-
tibody against myogenin. aCnA-infected cells demonstrate a cal-
cium-dependent expression pattern of myogenin similar to
control cells. The absence of the expression of myogenin at 0 mM
Ca  21 is not due to inefficient infection of the cells, because
aCnA-infected cells maintained in GM express myogenin at
higher levels than control cells. A portion of a membrane stained
for total protein with colloidal gold is shown to indicate relative
protein loading. The data are representative of three indepen-
dent experiments.
Figure 6. aCnA increases levels of myogenin mRNA
and activates transcription from a myogenin reporter
construct. (a) Primary myoblasts were infected with
either control (Ctrl) or aCnA retroviruses and main-
tained in GM. RNA samples were collected at vari-
ous time points and analyzed by Northern blotting
for myogenin mRNA. Expression of aCnA results in
an increase in myogenin mRNA compared with con-
trol cultures. A portion of an ethidium bromide–
stained gel containing 28S and 18S rRNAs demon-
strates relative RNA loading. The blot shown is
representative of two independent experiments. (b) Primary myoblasts containing a myogenin promoter reporter construct were in-
fected with either control or aCnA retroviruses. After 48 h in GM, the cultures were analyzed for luciferase activity. Expression of
aCnA results in a CSA-sensitive activation of the myogenin promoter. Each bar represents the mean 6 SEM of 3–4 independent exper-
iments each performed in triplicate. Statistical analyses were performed using one-way ANOVA with Bonferroni’s multiple comparison
test. *P , 0.01 vs Ctrl; **P , 0.001 vs aCnA. 
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except that the paradoxical increase was not observed
(data not shown). Since GFP-VIVIT expression inhibits
NFAT activity, but does not inhibit differentiation, we
conclude that NFAT is not an essential downstream target
of calcineurin during myogenesis. 
 
Discussion
 
The molecular mechanisms that initiate differentiation of
myoblasts are not well understood. Changes in muscle reg-
ulatory factors such as MyoD, Myf-5, and myogenin do oc-
cur early in differentiation (Megeney and Rudnicki, 1995;
Rudnicki and Jaenisch, 1995; Buckingham, 1996), but the
signaling pathways that regulate these changes have not
been delineated. A large body of work has demonstrated
that calcium and calcium-dependent pathways are re-
quired for myogenesis (Shainberg et al., 1969; Knudsen
and Horwitz, 1977; Knudsen, 1985; Lognonne and Wahr-
mann, 1986; Przybylski et al., 1989; Cottin et al., 1994;
Constantin et al., 1995; Barnoy et al., 1997, 1998; Temm-
Grove et al., 1999). For the most part, these earlier studies
linking calcium to differentiation focused on the clearly
identifiable cell fusion event, but since myoblasts pass
through multiple, temporally distinct phases before cell fu-
sion, the results of these studies may also reflect calcium-
dependent regulation at earlier stages in myogenesis.
Thus, it is not exactly clear where calcium acts in the myo-
genic pathway and whether multiple points of regulation
are present. The data presented in this paper suggest that
at least three distinct steps require calcium based on their
differing requirements for extracellular calcium: commit-
ment to differentiation, phenotypic differentiation, and
cell fusion.
Changes in the concentration of extracellular calcium
may inhibit differentiation for several reasons. (a) Ex-
tremely low levels of extracellular calcium may be toxic to
cells. This is unlikely due to the reversibility of the inhibi-
tion (Fig. 1 c) that has been noted by us as well as other
groups (Shainberg et al., 1969; Przybylski et al., 1989). (b)
Calcium available for intracellular signaling processes may
be decreased. During differentiation, the total cell calcium
increases, and decreases in extracellular calcium produce
similar decreases in intracellular calcium (Przybylski et al.,
1989). That extracellular calcium is directly needed for
intracellular signaling is shown by the ability of calcium
channel blockers to inhibit cell fusion and the expression
of creatine kinase (Seigneurin-Venin et al., 1996). (c) Ex-
tracellular proteins may require calcium for normal activ-
ity. The glycoprotein interactions that mediate cell aggre-
gation before fusion require calcium (Knudsen, 1985). A
combination of multiple mechanisms at multiple phases is
likely to account for the calcium requirement in differenti-
ation.
We demonstrate that calcineurin is a downstream effec-
tor for calcium in regulating myogenic commitment to dif-
ferentiation. Experiments using the calcineurin inhibitor
CSA demonstrated inhibition in the expression of myoge-
nin, the earliest known marker of skeletal muscle differen-
tiation. The effects of CSA on myogenic commitment sug-
gest a role for calcineurin in initiating myogenesis, but do
not rule out targets besides calcineurin. In smooth muscle
cells, increased cytosolic calcium concentrations resulting
from CSA treatment are due to a calcineurin-independent
pathway (Lo Russo et al., 1997). A calcineurin-indepen-
dent pathway has also been described for inhibition of ni-
tric oxide synthase activation by CSA in a glioma cell line
(Trajkovic et al., 1999). To rule out the involvement of cal-
cineurin-independent pathways, we used both a physiolog-
ical protein inhibitor and a constitutively active form of
calcineurin to modulate calcineurin activity in myoblasts.
Results using these methods conclusively show that cal-
cineurin participates in initiating myogenic differentiation.
Possibly, calcineurin also plays a role at later stages of
myogenesis, but this would not be detected in our assays
since inhibiting differentiation at the early stages would
also be detected as an inhibition of the later stages. Cal-
cineurin is unlikely to be the only downstream effector of
calcium in initiating differentiation, as the constitutively
active form of calcineurin could not induce differentiation
in the absence of extracellular calcium.
The calcium-dependent expression of myogenin and the
role of calcineurin in regulating myogenic initiation sug-
gest that changes in cytosolic calcium must occur early in
the myogenic program. Few studies quantitating the level
of calcium in myoblasts undergoing differentiation have
been performed at early time points. In one study, chang-
ing from a growth media to a differentiation media in-
creased cytosolic calcium in myoblasts from 90 to 128 nM
after 8 h (Constantin et al., 1995). Another study showed
that the exchangeable calcium content of differentiation-
arrested cells in 0.04 mM Ca
 
2
 
1
 
 increased significantly 2 h
Figure 7. Inhibition of NFAT activity by the expres-
sion of GFP-VIVIT does not inhibit myogenesis in
L6 muscle cell cultures. (a) Primary myoblasts were
infected with an NFAT responsive reporter and ei-
ther control (Ctrl) or GFP-VIVIT retroviruses. Cells
were induced to differentiate for 48 h in DM. Lu-
ciferase assays were performed on vehicle (V), iono-
mycin (I, 1 mM) plus PMA- (P, 10 nM), or IP plus
CSA- (C, 1 mM) treated cultures. GFP-VIVIT inhib-
its NFAT activity in skeletal muscle cells. Data are
reported as the fold increase over vehicle-treated control cells. Each bar represents the mean 6 SEM of three independent experiments
each performed in triplicate. (b) L6 myoblasts were infected with either control or GFP-VIVIT retroviruses and induced to differentiate
in DM. Cellular proteins were collected at various time points and analyzed by immunoblotting. GFP-VIVIT does not inhibit the ex-
pression of either myogenic marker. The blot shown is representative of two independent experiments. 
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after increasing media calcium concentration (Przybylski
et al., 1989). A study by Seigneurin-Venin et al. (1996) is
particularly relevant to our work, because it demonstrated
the importance of the dihydropyridine receptor in regulat-
ing calcium release from intracellular stores for creatine
kinase expression. Since the dihydropyridine receptor re-
quirement occurs at a step before phenotypic differentia-
tion, it may therefore represent a pathway for regulating
increases in cytosolic calcium necessary for the activation
of calcineurin.
The downstream effectors for calcineurin in regulating
the initiation of myogenesis are not known. Certainly,
transcriptional activation is a component as expression of
aCnA-activated transcription from pMyogLuc. However,
we detected only a relatively small increase in luciferase
levels after expression of aCnA, as compared with the rel-
atively large increase in the level of myogenin mRNA.
This suggests that calcineurin-dependent regulatory ele-
ments exist in the myogenin promoter outside of the re-
gion we used for our reporter. Alternatively, mRNA stabi-
lization may occur as a result of an increase in calcineurin
activity. Recently, calcineurin was shown to regulate the
stability of the acetylcholinesterase mRNA in C2C12 mus-
cle cells during differentiation (Luo et al., 1999).
The transcription factor NFAT is a potential target of
calcineurin during myogenesis. We have previously shown
the presence and activity of NFAT in skeletal muscle cells
(Abbott et al., 1998). Muscle cells express three NFAT
isoforms that differ in their ability to be activated and
undergo nuclear translocation at different stages of de-
velopment. However, our results show that calcineurin
substrates other than NFAT are in fact required for differ-
entiation, and novel calcineurin substrates may exist in
skeletal muscle cells. The muscle regulatory factor family
(Myf-5, MyoD, myogenin, MRF4) of transcription factors
plays a primary role in regulating myogenesis and are
themselves regulated by phosphorylation, and could there-
fore be potential targets for the phosphatase activity of
calcineurin. All of the muscle regulatory factors are inhib-
ited by cAMP-dependent protein kinase (Li et al., 1992),
and MyoD activity is inhibited by phosphorylation of a
threonine residue at position 115 (Liu et al., 1998). The
myocyte enhancer factor (MEF) family of transcription
factors also represent potential calcineurin targets. These
factors are required for differentiation as a dominant-neg-
ative form of MEF2 inhibits differentiation (Ornatsky et
al., 1997). The potential for MEFs as calcineurin targets is
highlighted by work demonstrating that the myogenin
gene is activated by posttranslational modifications of pre-
existing MEF2 (Buchberger et al., 1994). In addition, a re-
porter construct containing only a consensus MEF binding
site and a TATA-box was activated after overexpression
of a constitutively active form of calcineurin in skeletal
muscle cells (Chin et al., 1998).
Our results suggest that calcineurin plays a more funda-
mental role in myogenesis than has been previously de-
scribed. Several papers have described the necessity of cal-
cineurin activity during skeletal muscle hypertrophy in
vitro and in vivo (Dunn et al., 1999; Musaro et al., 1999;
Semsarian et al., 1999). Skeletal muscle hypertrophy using
in vivo models requires activation and differentiation of
resident satellite cells (Rosenblatt and Parry, 1992; Rosen-
blatt et al., 1994; Phelan and Gonyea, 1997). The results of
the in vivo
 
 
 
studies on the role of calcineurin in hypertro-
phy may, therefore, be consistent with our results. If satel-
lite cell differentiation requires calcineurin activity, then
inhibition of calcineurin would also inhibit hypertrophy.
However, at least one study using a model of functional
overload has reported that the prevention of hypertrophy
by CSA treatment was not due to an inhibition of satellite
cell differentiation (Dunn et al., 1999). Our results and the
models of calcineurin-dependent hypertrophy may repre-
sent distinct pathways.
In summary, we have defined a calcium-dependent
pathway that regulates the commitment of myoblasts to
the differentiation pathway. Calcineurin activity is both
necessary and sufficient in the presence of adequate extra-
cellular calcium to induce differentiation. This pathway is
independent of NF-AT activity. Future studies will iden-
tify the upstream signals that regulate calcium changes
early in myogenesis as well as the downstream targets of
calcineurin in skeletal muscle.
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